Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.89 [0.78, 1.01] | | < 1 | | 0% | 2 studies (2/-) | 96.8 % | some concern | not evaluable | moderate | crucial | - |
progression or deaths (PFS) | 1.03 [0.60, 1.76] | | < 1 | | 94% | 2 studies (2/-) | 46.3 % | some concern | not evaluable | moderate | important | - |
objective responses (ORR) | 0.89 [0.33, 2.43] | | > 1 | | 95% | 2 studies (2/-) | 41.1 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
AE (grade 3-5) | 0.76 [0.19, 3.00] | | < 1 | | 96% | 2 studies (2/-) | 65.4 % | some concern | not evaluable | moderate | non important | - |
AE leading to death (grade 5) | 3.61 [2.10, 6.20] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
AE leading to treatment discontinuation (any grade) | 1.32 [0.57, 3.08] | | < 1 | | 90% | 2 studies (2/-) | 25.9 % | some concern | not evaluable | moderate | non important | - |
STRAE (any grade) | 0.68 [0.23, 1.96] | | < 1 | | 94% | 2 studies (2/-) | 76.3 % | some concern | not evaluable | moderate | non important | - |
TRAE (any grade) | 0.08 [0.04, 0.14] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 0.31 [0.02, 4.36] | | < 1 | | 99% | 2 studies (2/-) | 80.5 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to death (grade 5) | 1.05 [0.26, 4.23] | | < 1 | | 0% | 2 studies (2/-) | 47.1 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
Adrenal insufficiency TRAE (grade 3-4) | 1.55 [0.12, 20.23] | | < 1 | | 0% | 2 studies (2/-) | 37.0 % | some concern | not evaluable | moderate | non important | - |
Anaemia TRAE (grade 3-4) | 0.14 [0.00, 5.49] | | < 1 | | 97% | 2 studies (2/-) | 84.9 % | some concern | not evaluable | moderate | non important | - |
Asthenia TRAE (grade 3-4) | 0.43 [0.06, 3.14] | | < 1 | | 69% | 2 studies (2/-) | 79.6 % | some concern | not evaluable | moderate | non important | - |
Colitis TRAE (grade 3-4) | 3.12 [0.62, 15.78] | | < 1 | | 0% | 2 studies (2/-) | 8.6 % | some concern | not evaluable | moderate | non important | - |
Constipation TRAE (grade 3-4) | 0.73 [0.14, 3.84] | | < 1 | | 0% | 2 studies (2/-) | 64.4 % | some concern | not evaluable | moderate | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.35 [0.07, 1.74] | | < 1 | | 0% | 2 studies (2/-) | 90.0 % | some concern | not evaluable | moderate | non important | - |
Diabetes TRAE (grade 3-4) | 2.11 [0.19, 23.33] | | < 1 | | 0% | 2 studies (2/-) | 27.3 % | some concern | not evaluable | moderate | non important | - |
Diarrhoea TRAE (grade 3-4) | 1.15 [0.48, 2.75] | | < 1 | | 0% | 2 studies (2/-) | 37.7 % | some concern | not evaluable | moderate | non important | - |
Fatigue TRAE (grade 3-4) | 0.70 [0.33, 1.47] | | < 1 | | 0% | 2 studies (2/-) | 82.9 % | some concern | not evaluable | moderate | non important | - |
Hepatitis TRAE (grade 3-4) | 2.11 [0.19, 23.33] | | < 1 | | 0% | 2 studies (2/-) | 27.3 % | some concern | not evaluable | moderate | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 1.55 [0.12, 20.23] | | < 1 | | 0% | 2 studies (2/-) | 37.0 % | some concern | not evaluable | moderate | non important | - |
Hypophysitis TRAE (grade 3-4) | 3.89 [0.41, 36.85] | | < 1 | | 0% | 2 studies (2/-) | 12.0 % | some concern | not evaluable | moderate | non important | - |
Hypothyroidism TRAE (grade 3-4) | 3.06 [0.31, 30.30] | | < 1 | | 0% | 2 studies (2/-) | 17.1 % | some concern | not evaluable | moderate | non important | - |
Leucopenia TRAE (grade 3-4) | 0.09 [0.00, 7.03] | | < 1 | | 89% | 2 studies (2/-) | 85.4 % | some concern | not evaluable | moderate | non important | - |
Myocarditis TRAE (grade 3-4) | 1.55 [0.12, 20.23] | | < 1 | | 0% | 2 studies (2/-) | 37.0 % | some concern | not evaluable | moderate | non important | - |
Myositis TRAE (grade 3-4) | 1.05 [0.07, 16.88] | | < 1 | | 0% | 2 studies (2/-) | 48.5 % | some concern | not evaluable | moderate | non important | - |
Nausea TRAE (grade 3-4) | 0.57 [0.20, 1.64] | | < 1 | | 28% | 2 studies (2/-) | 85.0 % | some concern | not evaluable | moderate | non important | - |
Nephritis TRAE (grade 3-4) | 2.11 [0.19, 23.33] | | < 1 | | 0% | 2 studies (2/-) | 27.3 % | some concern | not evaluable | moderate | non important | - |
Neutropenia TRAE (grade 3-4) | 0.08 [0.00, 14.71] | | < 1 | | 93% | 2 studies (2/-) | 82.2 % | some concern | not evaluable | moderate | non important | - |
Pancreatitis TRAE (grade 3-4) | 4.23 [0.47, 37.98] | | < 1 | | 0% | 2 studies (2/-) | 10.0 % | some concern | not evaluable | moderate | non important | - |
Pneumonitis TRAE (grade 3-4) | 3.70 [0.76, 17.95] | | < 1 | | 0% | 2 studies (2/-) | 5.2 % | some concern | not evaluable | moderate | non important | - |
Pruritus TRAE (grade 3-4) | 3.22 [0.30, 34.84] | | < 1 | | 0% | 2 studies (2/-) | 17.0 % | some concern | not evaluable | moderate | non important | - |
Rash TRAE (grade 3-4) | 2.23 [0.35, 14.10] | | < 1 | | 0% | 2 studies (2/-) | 19.8 % | some concern | not evaluable | moderate | non important | - |
Sarcoidosis TRAE (grade 3-4) | 1.05 [0.07, 16.88] | | < 1 | | 0% | 2 studies (2/-) | 48.5 % | some concern | not evaluable | moderate | non important | - |
Severe skin reaction TRAE (grade 3-4) | 2.46 [0.72, 8.32] | | < 1 | | 0% | 2 studies (2/-) | 7.5 % | some concern | not evaluable | moderate | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 0.14 [0.00, 5.55] | | < 1 | | 92% | 2 studies (2/-) | 84.9 % | some concern | not evaluable | moderate | non important | - |
Thyroiditis TRAE (grade 3-4) | 1.58 [0.12, 20.66] | | < 1 | | 0% | 2 studies (2/-) | 36.4 % | some concern | not evaluable | moderate | non important | - |
Vomiting TRAE (grade 3-4) | 0.49 [0.07, 3.55] | | < 1 | | 68% | 2 studies (2/-) | 76.1 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |